IDEAYA Biosciences (IDEAYA) is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and for enhancing immunotherapy response, and immuno-oncology therapies targeting the tumor micro-environment. IDEAYA, located in South San Francisco and San Diego, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology and small molecule drug discovery.
Jan 4, 2018, J.P. Morgan's 36th Annual Healthcare Conference on Wednesday, January 10, 2018. IDEAYA Biosciences to present at J.P. Morgan's Annual Healthcare Conference on Wednesday, January 10 at 1:30pm PT.
Sept 6, 2017, Citi's 12th Annual Biotech Conference September 6-7, 2017. IDEAYA Biosciences invited to participate in panel on Emerging Innovators at Citi's 12th Annual Biotech Conference in Boston, MA
Jan 3, 2017, BioSpace "NextGen" 2017. BioSpace names IDEAYA Biosciences as
one of the Top 20 Start-Ups to watch in 2017
Sept 19, 2016, FierceBiotech "Fierce 15" 2016. FierceBiotech names
IDEAYA Biosciences as one of its "Fierce 15" Biotech Companies of 2016
May 4, 2016, BioWorld Today Cover Story. Capital Ideaya: $46M take propels synthetic lethality; gene pairs kicked upstairs
Synthetic Lethality (SL) is a concept first identified in the model genetic system Drosophila melanogaster (fruit fly) and recapitulated in yeast and other organisms.